Syntekabio, an AI-based drug discovery and development company, starts operations in the United States
Syntekabio offers innovative AI drug discovery solutions for the global biopharmaceutical industry, including DeepMatcher® via a PaaS cloud service.
Syntekabio Inc (KOSDAQ:226330)
— Kilyoung Kim, CSO and President of Syntekabio USA
NEW YORK, NEW YORK, USA, August 12, 2022 /EINPresswire.com/ — Syntekabio, an artificial intelligence (AI) based on drug development, officially launched operations in the United States with a regional office in New York, Syntekabio USA. The company is headquartered in South Korea, where it is listed on the national stock exchange (KOSDAQ: 226330). Syntekabio USA will lead the company for its drug discovery cloud service platforms and pipeline drug candidates in the US and global markets.
The US-based company is led by Chief Scientific Officer (CSO) and President Kilyoung Kim, PhD, who reports to Syntekabio Founder and CEO Jongsun Jung, PhD. Dr. Kim is responsible for business development strategy and operations in the United States and globally.
“I am excited to join Syntekabio USA to lead the company’s AI-driven drug discovery business to the next level with my extensive experience in the US drug development industry,” said Dr Kim. . “Unlike other AI drug discovery competitors, Syntekabio’s unique technology solutions will provide customers with drug discovery cloud platform service without expert knowledge for their successful drug development.”
Syntekabio has developed a revolutionary DeepMatcher technology®, a proprietary beta cloud AI drug discovery platform, which screens over 1 billion commercially available compounds against over 600 target proteins, wild-type and mutated, identified through big data genomic analysis. DeepMatter® Efficiently derive new small molecule drug candidates and optimize complex three-dimensional structures of drug targets by adopting the best pose based on AI, receptor-ligand binding energy and molecular dynamics simulation.
“We are excited to bring our powerful supercomputing infrastructure and cloud-based AI drug discovery platform to the US market,” said Dr. Jung, CEO of Syntekabio. “We are confident that our cutting-edge technologies will continue to advance to add significant value through proven efficacy and help develop new drug candidates with a high success rate in the global market.”
The company’s latest innovations also include a new NEO-ARS™ antigen prediction platform, a NGS-ARS™ next-generation genome sequencing platform and a biomarker discovery platform for personalized genomic drug PGM-ARS™ .
Syntekabio is actively seeking opportunities to expand its business with pharmaceuticals, biotechnologies and investment companies through a cloud platform service, joint research projects using its AI platform technology, and pipeline licensing.
Syntekabio is a global drug discovery and development company based on artificial intelligence (AI) and big data. diseases and improve people’s lives. Learn more about DeepMatcher®NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com.